CN101808998A - 在离子性液体基质中制备孟鲁司特酸的方法 - Google Patents
在离子性液体基质中制备孟鲁司特酸的方法 Download PDFInfo
- Publication number
- CN101808998A CN101808998A CN200880109004A CN200880109004A CN101808998A CN 101808998 A CN101808998 A CN 101808998A CN 200880109004 A CN200880109004 A CN 200880109004A CN 200880109004 A CN200880109004 A CN 200880109004A CN 101808998 A CN101808998 A CN 101808998A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- ionic liquid
- ethyl
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 239000002253 acid Substances 0.000 title claims abstract description 28
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 title claims abstract description 22
- 229960005127 montelukast Drugs 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000002608 ionic liquid Substances 0.000 title claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 47
- -1 thiol compound Chemical class 0.000 claims abstract description 24
- 159000000000 sodium salts Chemical class 0.000 claims abstract description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 27
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 12
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 7
- LVNWRCUZCYLLND-UHFFFAOYSA-N 2-bromo-1-ethyl-3-methyl-2h-imidazole Chemical compound CCN1C=CN(C)C1Br LVNWRCUZCYLLND-UHFFFAOYSA-N 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 6
- 125000001246 bromo group Chemical group Br* 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Substances [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 3
- IBZJNLWLRUHZIX-UHFFFAOYSA-N 1-ethyl-3-methyl-2h-imidazole Chemical compound CCN1CN(C)C=C1 IBZJNLWLRUHZIX-UHFFFAOYSA-N 0.000 claims description 2
- 229910015892 BF 4 Inorganic materials 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- 229910021115 PF 6 Inorganic materials 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 229910018286 SbF 6 Inorganic materials 0.000 claims description 2
- LRCPOJGBEQAERD-UHFFFAOYSA-M [P].[Br-].C(CCC)[P+](CCCC)(CCCC)CCCC Chemical compound [P].[Br-].C(CCC)[P+](CCCC)(CCCC)CCCC LRCPOJGBEQAERD-UHFFFAOYSA-M 0.000 claims description 2
- RMLHVYNAGVXKKC-UHFFFAOYSA-N [SH2]=N.C(F)(F)F Chemical compound [SH2]=N.C(F)(F)F RMLHVYNAGVXKKC-UHFFFAOYSA-N 0.000 claims description 2
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 claims description 2
- 239000002585 base Substances 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 37
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 35
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000012044 organic layer Substances 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 150000002617 leukotrienes Chemical class 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 102000004377 Thiopurine S-methyltransferases Human genes 0.000 description 9
- 108090000958 Thiopurine S-methyltransferases Proteins 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- UKPXULFIISGBHG-UHFFFAOYSA-N cyclopropene Chemical compound [CH]1C=C1 UKPXULFIISGBHG-UHFFFAOYSA-N 0.000 description 9
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000001953 recrystallisation Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- UFPQIRYSPUYQHK-VRKJBCFNSA-N Leukotriene A4 Natural products CCCCCC=C/CC=C/C=C/C=C/[C@@H]1O[C@H]1CCCC(=O)O UFPQIRYSPUYQHK-VRKJBCFNSA-N 0.000 description 2
- OTZRAYGBFWZKMX-SHSCPDMUSA-N Leukotriene E4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(N)C(=O)O)C(O)CCCC(=O)O OTZRAYGBFWZKMX-SHSCPDMUSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- UFPQIRYSPUYQHK-WAQVJNLQSA-N leukotriene A4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@@H]1O[C@H]1CCCC(O)=O UFPQIRYSPUYQHK-WAQVJNLQSA-N 0.000 description 2
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 2
- OTZRAYGBFWZKMX-JUDRUQEKSA-N leukotriene E4 Chemical compound CCCCCC=CCC=C\C=C\C=C\[C@@H](SC[C@H](N)C(O)=O)[C@@H](O)CCCC(O)=O OTZRAYGBFWZKMX-JUDRUQEKSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 150000003527 tetrahydropyrans Chemical class 0.000 description 2
- KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 description 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- ZBMTVBAGMRDQOP-UHFFFAOYSA-N P(O)(O)(O)=O.[Cl].C1(=CC=CC=C1)C1=CC=CC=C1 Chemical compound P(O)(O)(O)=O.[Cl].C1(=CC=CC=C1)C1=CC=CC=C1 ZBMTVBAGMRDQOP-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 230000003570 biosynthesizing effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- WIJKCDNTPKNICK-UHFFFAOYSA-N cyclopropylmethyl acetate Chemical compound CC(=O)OCC1CC1 WIJKCDNTPKNICK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Quinoline Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (8)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070101486A KR101072896B1 (ko) | 2007-10-09 | 2007-10-09 | 이온성 액체 매개체를 이용한 몬테루카스트산의 제조 방법 |
KR10-2007-0101486 | 2007-10-09 | ||
PCT/KR2008/005794 WO2009048236A1 (en) | 2007-10-09 | 2008-10-01 | Method for the preparation of montelukast acid in ionic liquid medium |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101808998A true CN101808998A (zh) | 2010-08-18 |
CN101808998B CN101808998B (zh) | 2012-10-24 |
Family
ID=40549354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008801090046A Expired - Fee Related CN101808998B (zh) | 2007-10-09 | 2008-10-01 | 在离子性液体基质中制备孟鲁司特酸的方法 |
Country Status (18)
Country | Link |
---|---|
US (1) | US8426599B2 (zh) |
EP (1) | EP2195295B1 (zh) |
JP (1) | JP5210389B2 (zh) |
KR (1) | KR101072896B1 (zh) |
CN (1) | CN101808998B (zh) |
AR (1) | AR068755A1 (zh) |
CA (1) | CA2701912C (zh) |
CL (1) | CL2008002996A1 (zh) |
DK (1) | DK2195295T3 (zh) |
ES (1) | ES2398732T3 (zh) |
HR (1) | HRP20130103T1 (zh) |
MX (1) | MX2010001864A (zh) |
PE (2) | PE20091369A1 (zh) |
PL (1) | PL2195295T3 (zh) |
PT (1) | PT2195295E (zh) |
RU (1) | RU2436774C1 (zh) |
TW (1) | TWI350284B (zh) |
WO (1) | WO2009048236A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103570618A (zh) * | 2013-09-30 | 2014-02-12 | 浙江车头制药股份有限公司 | 一种孟鲁司特钠盐的制备方法 |
CN105294556A (zh) * | 2014-06-06 | 2016-02-03 | 上海迪赛诺化学制药有限公司 | 一种制备孟鲁司特酸的方法 |
CN111892535A (zh) * | 2020-08-27 | 2020-11-06 | 鲁南制药集团股份有限公司 | 一种孟鲁司特钠的合成方法 |
CN111961083A (zh) * | 2020-08-27 | 2020-11-20 | 鲁南制药集团股份有限公司 | 一种孟鲁司特钠中间体化合物 |
CN113330006A (zh) * | 2019-09-26 | 2021-08-31 | 大峰Ls株式会社 | 以离子液体为介质的艾氟康唑的新型制备方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP1000425A2 (en) | 2010-08-11 | 2012-03-28 | Richter Gedeon Nyrt | Process for the production of montelukast sodium |
KR20210042412A (ko) | 2018-09-06 | 2021-04-19 | 주식회사 이노파마스크린 | 천식 또는 파킨슨병 치료를 위한 방법 및 조성물 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19875039I2 (de) | 1990-10-12 | 2003-05-22 | Merck Frosst Canada Inc | Ungesaettigte Hydroxyalkylchinolinsaeuren als Leukotrien-Antagonisten |
TW448160B (en) * | 1993-12-28 | 2001-08-01 | Merck & Co Inc | Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists |
US5523477A (en) | 1995-01-23 | 1996-06-04 | Merck & Co., Inc. | Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid |
WO2005074935A1 (en) * | 2004-01-30 | 2005-08-18 | Teva Pharmaceutical Industries Ltd. | Montelukast free acid polymorphs |
MXPA06012220A (es) | 2004-04-21 | 2007-07-18 | Teva Pharma | Procesos para preparar sodio de montelukast. |
JP2006089463A (ja) * | 2004-08-24 | 2006-04-06 | Sumitomo Chemical Co Ltd | アリールエーテル類の製造方法 |
WO2006064269A2 (en) * | 2004-12-17 | 2006-06-22 | Cipla Limited | Salts of leukotriene antagonist montelukast |
GB0500029D0 (en) * | 2005-01-04 | 2005-02-09 | Univ Belfast | Basic ionic liquids |
AU2006302237C1 (en) | 2005-10-07 | 2012-11-08 | The University Of Alabama | Multi-functional ionic liquid compositions |
EP1783117A1 (en) | 2005-11-04 | 2007-05-09 | Esteve Quimica, S.A. | Process for the preparation of a leukotriene antagonist and intermediates thereof |
EP1968943B1 (en) | 2005-12-13 | 2013-01-23 | MSN Laboratories Limited | An improved process for the preparation of montelukast and its pharmaceutically acceptable salts |
US20090182148A1 (en) * | 2005-12-23 | 2009-07-16 | Harmander Singh Pal Chawla | Process for the manufacture of montelukast sodium |
WO2007096889A2 (en) * | 2006-02-27 | 2007-08-30 | Chemagis Ltd. | Process for preparing montelukast and salts thereof |
KR100774088B1 (ko) | 2006-12-14 | 2007-11-06 | 한미약품 주식회사 | 몬테루카스트의 제조방법 및 이에 사용되는 중간체 |
-
2007
- 2007-10-09 KR KR1020070101486A patent/KR101072896B1/ko active IP Right Grant
-
2008
- 2008-10-01 PL PL08838092T patent/PL2195295T3/pl unknown
- 2008-10-01 JP JP2010528789A patent/JP5210389B2/ja not_active Expired - Fee Related
- 2008-10-01 WO PCT/KR2008/005794 patent/WO2009048236A1/en active Application Filing
- 2008-10-01 DK DK08838092.8T patent/DK2195295T3/da active
- 2008-10-01 CA CA2701912A patent/CA2701912C/en not_active Expired - Fee Related
- 2008-10-01 MX MX2010001864A patent/MX2010001864A/es active IP Right Grant
- 2008-10-01 CN CN2008801090046A patent/CN101808998B/zh not_active Expired - Fee Related
- 2008-10-01 RU RU2010118618/04A patent/RU2436774C1/ru not_active IP Right Cessation
- 2008-10-01 ES ES08838092T patent/ES2398732T3/es active Active
- 2008-10-01 EP EP08838092A patent/EP2195295B1/en not_active Not-in-force
- 2008-10-01 PT PT88380928T patent/PT2195295E/pt unknown
- 2008-10-01 US US12/674,118 patent/US8426599B2/en not_active Expired - Fee Related
- 2008-10-08 AR ARP080104395A patent/AR068755A1/es unknown
- 2008-10-08 TW TW097138680A patent/TWI350284B/zh not_active IP Right Cessation
- 2008-10-09 PE PE2008001742A patent/PE20091369A1/es not_active Application Discontinuation
- 2008-10-09 PE PE2013000260A patent/PE20131219A1/es not_active Application Discontinuation
- 2008-10-09 CL CL2008002996A patent/CL2008002996A1/es unknown
-
2013
- 2013-02-06 HR HRP20130103AT patent/HRP20130103T1/hr unknown
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103570618A (zh) * | 2013-09-30 | 2014-02-12 | 浙江车头制药股份有限公司 | 一种孟鲁司特钠盐的制备方法 |
CN105294556A (zh) * | 2014-06-06 | 2016-02-03 | 上海迪赛诺化学制药有限公司 | 一种制备孟鲁司特酸的方法 |
CN113330006A (zh) * | 2019-09-26 | 2021-08-31 | 大峰Ls株式会社 | 以离子液体为介质的艾氟康唑的新型制备方法 |
CN113330006B (zh) * | 2019-09-26 | 2023-11-07 | 大峰Ls株式会社 | 以离子液体为介质的艾氟康唑的新型制备方法 |
CN111892535A (zh) * | 2020-08-27 | 2020-11-06 | 鲁南制药集团股份有限公司 | 一种孟鲁司特钠的合成方法 |
CN111961083A (zh) * | 2020-08-27 | 2020-11-20 | 鲁南制药集团股份有限公司 | 一种孟鲁司特钠中间体化合物 |
CN111892535B (zh) * | 2020-08-27 | 2023-04-11 | 鲁南制药集团股份有限公司 | 一种孟鲁司特钠的合成方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2195295B1 (en) | 2013-01-23 |
KR20090036349A (ko) | 2009-04-14 |
JP2011500555A (ja) | 2011-01-06 |
DK2195295T3 (da) | 2013-05-06 |
US8426599B2 (en) | 2013-04-23 |
CA2701912A1 (en) | 2009-04-16 |
MX2010001864A (es) | 2010-03-15 |
PT2195295E (pt) | 2013-02-28 |
PL2195295T3 (pl) | 2013-06-28 |
CA2701912C (en) | 2013-04-02 |
KR101072896B1 (ko) | 2011-10-17 |
ES2398732T3 (es) | 2013-03-21 |
PE20131219A1 (es) | 2013-11-16 |
TWI350284B (en) | 2011-10-11 |
HRP20130103T1 (hr) | 2013-02-28 |
US20110105757A1 (en) | 2011-05-05 |
CN101808998B (zh) | 2012-10-24 |
JP5210389B2 (ja) | 2013-06-12 |
CL2008002996A1 (es) | 2009-04-13 |
EP2195295A1 (en) | 2010-06-16 |
PE20091369A1 (es) | 2009-10-01 |
EP2195295A4 (en) | 2011-04-13 |
TW200920737A (en) | 2009-05-16 |
WO2009048236A1 (en) | 2009-04-16 |
AR068755A1 (es) | 2009-12-02 |
RU2436774C1 (ru) | 2011-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101808998B (zh) | 在离子性液体基质中制备孟鲁司特酸的方法 | |
CN101558042B (zh) | 制备孟鲁司特的方法以及其中使用的中间体 | |
CN103025727B (zh) | HMG-CoA还原酶抑制剂及其中间体的制备方法 | |
CN102786448B (zh) | 一种合成belinostat的方法 | |
JP2018523633A5 (zh) | ||
CN103483269A (zh) | 瑞舒伐他汀钙及其中间体的制备方法 | |
CN104610359A (zh) | 一种制备磷酸特地唑胺的关键中间体及其制备方法 | |
WO2000053569A1 (fr) | Procede de preparation d'un 2-[2-(4-benzene alkyl)-ethyl]-2-amino-propadeniol et son produit intermediaire | |
CN102164897A (zh) | 制备孟鲁司特钠盐的方法 | |
JP6240346B2 (ja) | ロスバスタチンカルシウムを製造するための中間体化合物、及びそれを用いてロスバスタチンカルシウムを製造する方法 | |
CN104788387A (zh) | 高纯度瑞舒伐他汀钙的制备方法 | |
CN104072415A (zh) | 一种匹伐他汀钙的制备方法 | |
CN104016916A (zh) | 一种匹伐他汀钙中间体的制备方法 | |
CN105541711A (zh) | 一种孟鲁司特的制备方法 | |
CN100475807C (zh) | 一种3-甲基-7,8-二羟基异色满酮-4的合成方法 | |
CN102816114B (zh) | 一种HMG-CoA还原酶抑制剂的制备方法 | |
CN102718718B (zh) | 一种3,5-二溴-4-(5-苯并咪唑氧基)苯乙酸的制备方法 | |
CN104513222A (zh) | 一种药物中间体的合成方法 | |
KR20130078086A (ko) | 피타바스타틴 헤미칼슘의 제조방법 | |
JP2006176538A (ja) | テトラゾール化合物の製造法 | |
WO2012114347A1 (en) | Synthesis of chiral substituted benzenes and related aromatic compounds containing 1,2 diols protected as diacetal groups |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SOUTH KOREA-US HOLDINGS CO., LTD. Free format text: FORMER OWNER: HANMI PHARM. CO., LTD. Effective date: 20101220 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: GYEONGGI-DO, SOUTH KOREA TO: SEOUL, SOUTH KOREA |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20101220 Address after: Seoul, South Kerean Applicant after: Hanmi Pharm Ind Co.,Ltd. Address before: Gyeonggi Do, South Korea Applicant before: Hanmi Pharm. Co., Ltd. |
|
C53 | Correction of patent for invention or patent application | ||
CB02 | Change of applicant information |
Address after: South Korea 445-813 Gyeonggi Do China city east beach east beach is Hing Road 550 GA Applicant after: Hanmi Holdings Co., Ltd. Address before: Seoul, South Kerean Applicant before: Hanmi Pharm Ind Co.,Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: HANMI HOLDINGS CO., LTD. TO: HANMI SCIENCE CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121024 Termination date: 20171001 |
|
CF01 | Termination of patent right due to non-payment of annual fee |